Arch Therapeutics Inc (ARTH) Given Consensus Rating of “Buy” by Brokerages
Shares of Arch Therapeutics Inc (NASDAQ:ARTH) have earned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $2.83.
A number of equities research analysts recently weighed in on ARTH shares. Zacks Investment Research upgraded Arch Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Arch Therapeutics in a research report on Monday, September 18th. Ifs Securities restated an “outperform” rating on shares of Arch Therapeutics in a research report on Tuesday, July 25th. Finally, ValuEngine upgraded Arch Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th.
Shares of Arch Therapeutics (NASDAQ ARTH) traded up 0.60% during mid-day trading on Wednesday, reaching $0.79. The company’s stock had a trading volume of 69,854 shares. Arch Therapeutics has a 52-week low of $0.41 and a 52-week high of $0.89. The firm has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.63. The firm’s market cap is $119.11 million.
About Arch Therapeutics
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.